BiotechTube

Ganciclovir

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cytomegalovirus Infections

Conditions

Cytomegalovirus Infections

Trial Timeline

Sep 15, 2020 → Sep 15, 2022

NCT ID
NCT04478474

About Ganciclovir

Ganciclovir is a pre-clinical stage product being developed by Merck for Cytomegalovirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT04478474. Target conditions include Cytomegalovirus Infections.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT04478474Pre-clinicalCompleted

Competing Products

20 competing products in Cytomegalovirus Infections

See all competitors
ProductCompanyStageHype Score
ASP0113 + PlaceboAstellas PharmaPhase 2
52
ASP0113 + PlaceboAstellas PharmaPhase 3
77
Letermovir oral granules + Letermovir tablet + Letermovir intravenousMerckPhase 2
52
Letermovir 240 mg Oral TabletMerckPhase 2
52
Letermovir tablet + Letermovir IVMerckPhase 3
77
LetermovirMerckPhase 1
33
LetermovirMerckApproved
85
Letermovir 480 MG [Prevymis]MerckPhase 2
52
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose IDMerckPhase 1
33
Letermovir + PlaceboMerckPhase 3
77
LetermovirMerckPhase 2
52
V160 + PlaceboMerckPhase 2
52
V160MerckPhase 1
33
LetermovirMerckPhase 3
77
LetermovirMerckPhase 3
77
Valganciclovir + GanciclovirRochePhase 3
77
Zidovudine + Didanosine + GanciclovirRochePhase 1
33
ValganciclovirRochePre-clinical
23
Foscarnet sodium + GanciclovirRochePhase 1
33
Valganciclovir + ValganciclovirRochePhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85